These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 14506952)

  • 21. Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study.
    Greendale GA; Espeland M; Slone S; Marcus R; Barrett-Connor E;
    Arch Intern Med; 2002 Mar; 162(6):665-72. PubMed ID: 11911720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of postmenopausal bone loss by low and conventional doses of calcitriol or conjugated equine estrogen.
    Ongphiphadhanakul B; Piaseu N; Tung SS; Chailurkit L; Rajatanavin R
    Maturitas; 2000 Feb; 34(2):179-84. PubMed ID: 10714913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hormone replacement therapy improves distal radius bone structure by endocortical mineral deposition.
    Muller ME; Webber CE; Adachi JD
    Can J Physiol Pharmacol; 2003 Oct; 81(10):952-8. PubMed ID: 14608412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial.
    Palomba S; Orio F; Russo T; Falbo A; Tolino A; Manguso F; Nunziata V; Mastrantonio P; Lombardi G; Zullo F
    Osteoporos Int; 2005 Aug; 16(8):943-52. PubMed ID: 15739035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.
    Cauley JA; Robbins J; Chen Z; Cummings SR; Jackson RD; LaCroix AZ; LeBoff M; Lewis CE; McGowan J; Neuner J; Pettinger M; Stefanick ML; Wactawski-Wende J; Watts NB;
    JAMA; 2003 Oct; 290(13):1729-38. PubMed ID: 14519707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.
    Wimalawansa SJ
    Am J Med; 1998 Mar; 104(3):219-26. PubMed ID: 9552083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial.
    Greenspan SL; Resnick NM; Parker RA
    JAMA; 2003 May; 289(19):2525-33. PubMed ID: 12759324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of different treatment modalities for postmenopausal patients with osteopenia: hormone replacement therapy, calcitonin and clodronate.
    Tiraş MB; Noyan V; Yildiz A; Biberoğlu K
    Climacteric; 2000 Jun; 3(2):92-101. PubMed ID: 11910657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects on bone of oral hormone replacement therapy initiated 2 years after ovariectomy in young adult monkeys.
    Jayo MJ; Register TC; Carlson CS
    Bone; 1998 Oct; 23(4):361-6. PubMed ID: 9763148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women.
    Harris ST; Eriksen EF; Davidson M; Ettinger MP; Moffett AH; Baylink DJ; Crusan CE; Chines AA
    J Clin Endocrinol Metab; 2001 May; 86(5):1890-7. PubMed ID: 11344179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alveolar and postcranial bone density in postmenopausal women receiving hormone/estrogen replacement therapy: a randomized, double-blind, placebo-controlled trial.
    Civitelli R; Pilgram TK; Dotson M; Muckerman J; Lewandowski N; Armamento-Villareal R; Yokoyama-Crothers N; Kardaris EE; Hauser J; Cohen S; Hildebolt CF
    Arch Intern Med; 2002 Jun; 162(12):1409-15. PubMed ID: 12076241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early postmenopausal bone loss is prevented by estrogen and partially by 1alpha-OH-vitamin D3: therapeutic effects of estrogen and/or 1alpha-OH-vitamin D3.
    Gorai I; Chaki O; Taguchi Y; Nakayama M; Osada H; Suzuki N; Katagiri N; Misu Y; Minaguchi H
    Calcif Tissue Int; 1999 Jul; 65(1):16-22. PubMed ID: 10369728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peripheral quantitative computed tomography (pQCT) is useful for monitoring bone mineral density of the patients who receive hormone replacement therapy.
    Sawada K; Morishige K; Ohmichi M; Nishio Y; Yamamoto T; Hayakawa J; Mabuchi S; Isobe A; Sasaki H; Sakata M; Tasaka K; Murata Y
    Maturitas; 2007 Apr; 56(4):343-9. PubMed ID: 17010541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of exercise training added to ongoing hormone replacement therapy on bone mineral density in frail elderly women.
    Villareal DT; Binder EF; Yarasheski KE; Williams DB; Brown M; Sinacore DR; Kohrt WM
    J Am Geriatr Soc; 2003 Jul; 51(7):985-90. PubMed ID: 12834519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of postmenopausal bone loss with exchange for short-term HRT for 1alpha-hydroxycholecalciferol.
    Ushiroyama T; Ikeda A; Sakai M; Higashiyama T; Ueki M
    Maturitas; 2003 Jun; 45(2):119-27. PubMed ID: 12787970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Combination Therapy of Alendronate and Hormonal Therapy on Bone Mineral Density in Postmenopausal Korean Women: Multicenter, Randomized Controlled Clinical Trial.
    Yoon BK; Lee DY; Park MC; Cho SH; Park HM; Choi YM
    J Korean Med Sci; 2017 Jun; 32(6):992-998. PubMed ID: 28480658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial.
    Komulainen MH; Kröger H; Tuppurainen MT; Heikkinen AM; Alhava E; Honkanen R; Saarikoski S
    Maturitas; 1998 Nov; 31(1):45-54. PubMed ID: 10091204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: a population-based 5-year randomized trial.
    Komulainen M; Kröger H; Tuppurainen MT; Heikkinen AM; Alhava E; Honkanen R; Jurvelin J; Saarikoski S
    J Clin Endocrinol Metab; 1999 Feb; 84(2):546-52. PubMed ID: 10022414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
    J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial.
    Komulainen M; Kröger H; Tuppurainen MT; Heikkinen AM; Honkanen R; Saarikoski S
    Osteoporos Int; 2000; 11(3):211-8. PubMed ID: 10824236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.